Chongqing Peg-Bio Biopharm Co., Ltd.
Quick facts
Phase 3 pipeline
- PJ009 · Oncology
PJ009 is a monoclonal antibody targeting PD-1.
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Chongqing Peg-Bio Biopharm Co., Ltd. portfolio CI brief
- Chongqing Peg-Bio Biopharm Co., Ltd. pipeline updates RSS
Frequently asked questions about Chongqing Peg-Bio Biopharm Co., Ltd.
What is Chongqing Peg-Bio Biopharm Co., Ltd.'s pipeline?
Chongqing Peg-Bio Biopharm Co., Ltd. has 1 drugs in Phase 3, 0 in Phase 2, 3 in Phase 1. Late-stage candidates include PJ009.
Related
- Sector hub: All tracked pharma companies